Cargando…
P080 Comparison of efficacy of innovator molecule of itraconazole with generic forms of itraconazole in treatment naïve subjects with chronic pulmonary aspergillosis
POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM: OBJECTIVE: Itraconazole capsule has a variable and unpredictable bioavailability. Whether generic brands of itraconazole are as effective as the innovator molecule in the treatment of subjects with chronic pulmonary aspergillosis (CPA) is u...
Autores principales: | Sehgal, Inderpaul, Vinay, Keshavamurth, Agarwal, Ritesh, Rudramurth, Shivaprakash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509747/ http://dx.doi.org/10.1093/mmy/myac072.P080 |
Ejemplares similares
-
The minimal important difference of six-minute walk test in subjects with chronic pulmonary aspergillosis treated with six-months of oral itraconazole
por: Sehgal, Inderpaul S., et al.
Publicado: (2023) -
Itraconazole in chronic pulmonary aspergillosis: In whom, for how long, and at what dose?
por: Maturu, Venkata Nagarjuna, et al.
Publicado: (2015) -
Skin rash during treatment with generic itraconazole
por: De Vuono, Antonio, et al.
Publicado: (2014) -
Bioequivalence of Orally Administered Generic, Compounded, and Innovator‐Formulated Itraconazole in Healthy Dogs
por: Mawby, D.I., et al.
Publicado: (2013) -
P408 Evaluation of fungal serum biomarkers in the diagnosis and for monitoring patients with post tuberculosis chronic pulmonary aspergillosis
por: Singh, Shreya, et al.
Publicado: (2022)